Skip to main content

Advertisement

Log in

ASO Visual Abstract: FOLFIRINOX or Gemcitabine Based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Institutional, Patient-Level Meta-Analysis and Systematic Review

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kuno Lehmann MD, PhD.

Ethics declarations

Disclosure

Sarah Hoffe: Galera Pharmaceuticals, Institutional Principal Investigator for the GRECO-2 randomized international study for which my cancer center receives funding to support the trial, it is a pancreas trial that includes SBRT.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eshmuminov, D., Aminjonov, B., Palm, R.F. et al. ASO Visual Abstract: FOLFIRINOX or Gemcitabine Based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Institutional, Patient-Level Meta-Analysis and Systematic Review. Ann Surg Oncol 30, 4431–4432 (2023). https://doi.org/10.1245/s10434-023-13489-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13489-1

Navigation